Insilico Medicine, a clinical-stage biotechnology company leveraging generative AI for drug discovery, announced on March 13 that it has secured $110 million in Series E financing led by Value Partners Group. The funding will be used to advance its AI-powered platforms and expand its pipeline of novel therapeutics, focusing on refining machine learning models, expanding robotics capabilities, and accelerating clinical trials for treatments targeting conditions such as idiopathic pulmonary fibrosis.
Insilico has established partnerships with major pharmaceutical companies like Fosun Pharma and Sanofi, contributing to a robust revenue stream through out-licensing deals valued at over $2.1 billion. This financing will further strengthen the company’s position in AI-driven biopharmaceutical research and development, enabling broader applications across the life sciences sector.
Insilico Medicine Secures Series E Financing
Insilico Medicine has secured $100 million in Series E financing led by Value Partners Group. This funding will support the advancement of its AI-driven drug discovery platform, Pharma.AI, which leverages deep learning models for target identification and molecular structure generation.
The company has made significant strides in applying advanced machine learning techniques such as deep generative models, reinforcement learning, and transformers to enhance drug discovery processes. These methods form a robust framework for innovative development across various therapeutic areas, including cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune conditions, and aging-related illnesses.
Insilico Medicine’s pipeline includes 30 assets, with 10 having received IND clearance. A notable lead candidate is Rentosertib, currently in Phase IIa trials for idiopathic pulmonary fibrosis. Early studies have demonstrated favorable safety profiles and efficacy.
The company has established collaborations valued at over $1.4 billion with industry leaders such as Sanofi, Exelixis, and Menarini. Additionally, Insilico Medicine has generated significant revenue through out-licensing deals totaling over $2.1 billion, showcasing the commercial potential of its technology.
Looking ahead, Insilico Medicine plans to further leverage its AI-powered biopharmaceutical development capabilities. The company aims to expand its pipeline and strengthen collaborations with industry partners to effectively address diverse medical challenges.
More information
External Link: Click Here For More
